Nektar Therapeutics (NKTR) stock jumped 5.43% in pre-market trading on Monday, continuing its impressive rally that has seen shares nearly triple in value over the past three months. The biotech company's stock has been on a tear, with a staggering 149% increase in the last 90 days and a year-to-date gain exceeding 288%, attracting significant investor attention.

The pre-market surge comes as analysts debate the company's valuation and growth prospects. Some analysts view Nektar as undervalued, with the most optimistic projections suggesting a fair value of $93.86, implying a potential 40% upside from recent closing prices. This bullish outlook is largely driven by the promise of REZPEG, Nektar's candidate for atopic dermatitis, which has shown strong initial Phase IIb data. The global market for atopic dermatitis treatments is expected to reach nearly $30 billion by 2033, positioning Nektar to potentially tap into substantial new revenue streams.

However, the recent rally has also raised concerns about overvaluation. Nektar's price-to-sales ratio of 17x significantly exceeds the US Pharmaceuticals industry average of 4x and the peer average of 10.4x. This discrepancy suggests that much of the company's future potential may already be priced into the stock. Investors should also be mindful of the risks associated with the biotech sector, including the company's ongoing net losses and heavy reliance on the success of REZPEG's development and commercialization. As the market opens, all eyes will be on Nektar to see if this pre-market momentum can be sustained amidst the mixed analyst opinions and valuation debates.